Cantor Fitzgerald analyst Kristen Kluska lowered the firm’s price target on Sarepta to $165 from $178 and keeps an Overweight rating on the shares. The firm has reduced its estimate of the probability of success for SRP-9001 to 70% from 75% after the announcement of an Advisory Committee meeting, the analyst tells investors in a research note. The firm believes that the Sarepta team is confident in its preparation for an AdCom, which was the assumption when the Biologics License Application was submitted.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- BofA keeps Buy on Sarepta, trims target after FDA pivots on SRP-9001 adcom
- Sarepta price target lowered to $139 from $144 at Credit Suisse
- Sarepta Plunges after Regulatory Update
- Sarepta says advisory committee meeting to be held for SRP-9001
- Sarepta Therapeutics Skyrockets after String of Good News